A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

被引：0
|
作者：
Kelly, K
Mikhaeel-Kamel, N
Pan, ZX
Murphy, J
Prindiville, S
Bunn, PA
机构：
[1] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA
[2] Univ Colorado, Ctr Canc, Lung Canc Program, Denver, CO 80262 USA
[3] Univ Colorado, Ctr Canc, Dept Prevent Med & Biostat, Denver, CO 80262 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.
引用
收藏
页码：3474 / 3479
页数：6
相关论文
共 50 条
  • [31] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [32] Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer
    Kikuchi, J
    Yamazaki, K
    Kinoshita, I
    Asahina, H
    Imura, M
    Kikuchi, E
    Konishi, J
    Shinagawa, N
    Oki, H
    Dosaka-Akita, H
    Nishimura, M
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (09) : 505 - 509
  • [33] Phase I trial of dexamethasone (Dex), carboplatin (C) and gemcitabine (G) in untreated non-small cell lung cancer (NSCLC)
    Rinehart, J
    Robert, F
    Davidson, S
    DeShazo, M
    Buzby, L
    Clould, G
    [J]. LUNG CANCER, 2005, 49 : S266 - S267
  • [34] Phase I trial of dexamethasone (Dex), carboplatin (C) and gemcitabine (G) in untreated non-small cell lung cancer (NSCLC).
    Rinehart, JJ
    Davidson, S
    Deshazo, M
    Cloud, G
    Busby, L
    Robert, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 648S - 648S
  • [35] Phase I study of irinotecan and gemcitabine in previously untreated, patients with advanced non-small cell lung cancer
    Takatani, Hiroshi
    Soda, Hiroshi
    Nakamura, Yoichi
    Kinoshita, Akitoshi
    Fukuda, Masaaki
    Nagashima, Seiji
    Fukuda, Minoru
    Soejima, Yoshifumi
    Nakano, Hirofumi
    Oka, Mikio
    Kohno, Shigeru
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (05) : 353 - 357
  • [36] A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
    Soejima, Kenzo
    Naoki, Katsuhiko
    Ishioka, Kota
    Nakamura, Morio
    Nakatani, Michie
    Kawada, Ichiro
    Watanabe, Hideo
    Nakachi, Ichiro
    Yasuda, Hiroyuki
    Satomi, Ryosuke
    Nakayama, Sohei
    Yoda, Satoshi
    Ikemura, Sinnosuke
    Terai, Hideki
    Sato, Takashi
    Ohgino, Keiko
    Arai, Daisuke
    Tani, Tetsuo
    Kuroda, Aoi
    Nishino, Makoto
    Betsuyaku, Tomoko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 513 - 519
  • [37] Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)
    Kosmidis, P
    Kalofonos, C
    Syrigos, K
    Skarlos, D
    Fountzilas, G
    Nicolaides, C
    Bafaloukos, D
    Samantas, E
    Bakogiannis, C
    Dimopoulos, A
    [J]. LUNG CANCER, 2005, 49 : S34 - S34
  • [38] A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
    Kenzo Soejima
    Katsuhiko Naoki
    Kota Ishioka
    Morio Nakamura
    Michie Nakatani
    Ichiro Kawada
    Hideo Watanabe
    Ichiro Nakachi
    Hiroyuki Yasuda
    Ryosuke Satomi
    Sohei Nakayama
    Satoshi Yoda
    Sinnosuke Ikemura
    Hideki Terai
    Takashi Sato
    Keiko Ohgino
    Daisuke Arai
    Tetsuo Tani
    Aoi Kuroda
    Makoto Nishino
    Tomoko Betsuyaku
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 513 - 519
  • [39] Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)
    Kosmidis, PA
    Kalofonos, C
    Syrigos, K
    Skarlos, D
    Fountzilas, G
    Nicolaides, C
    Bafaloukos, D
    Samantas, E
    Bakogiannis, C
    Dimopoulos, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 621S - 621S
  • [40] Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer
    Yanagitani, Noriko
    Tsuchiya, Satoshi
    Kaira, Kyoichi
    Sunaga, Noriaki
    Tsuchiya, Yukiko
    Sato, Koji
    Watanabe, Satoru
    Nomura, Shiro
    Sakai, Shuzo
    Saito, Ryusei
    Mori, Masatomo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (05): : 487 - 491
12345